Ana Cámara

Finding genetically-supported drug targets for Parkinson’s disease using Mendelian randomization of the druggable genome

Catherine S. Storm, Demis A. Kia, Mona Mohammad Almramhi et al. · Nature Communications · 2021 · 214 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Mitochondria function associated genes contribute to Parkinson’s Disease risk and later age at onset

Kimberley J. Billingsley, Inês A. Barbosa, Sara Bandrés‐Ciga et al. · npj Parkinson s Disease · 2019 · 161 citations · Full text

Life Sciences, Genetics, Neuroscience +17

Combined dementia-risk biomarkers in Parkinson's disease: A prospective longitudinal study

Yaroslau Compta, Joana B. Pereira, José Ríos et al. · Parkinsonism & Related Disorders · 2013 · 158 citations

Medicine, Neurology, Neuroscience +14

Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson’s disease

Yaroslau Compta, Tony Valente, Josep Saura et al. · Journal of Neurology · 2014 · 100 citations · Full text

Life Sciences, Neurology, Neuroscience +15

Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry

Maríateresa Buongiorno, Francesca Antonelli, Ana Cámara et al. · Parkinsonism & Related Disorders · 2015 · 89 citations

Medicine, Neurology, Pharmacotherapy +10